HEALTH CARE UTILIZATION (HCU) BY BREAST CANCER (BC) AND NON-HODGKIN LYMPHOMA (NHL) PATIENTS WITH CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (FN) IN THE NETHERLANDS
Author(s)
Issa DE1, van Herk-Sukel MPP2, Gelderblom H3, Houweling LMA2, Jager A4, De La Orden M5, Lugtenburg PJ4, van der Werf-Langenberg ME6, Nortier JWR3, de Jong FA61VU University Medical Center, Amsterdam, Netherlands, 2PHARMO Institute, Utrecht, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Erasmus University Medical Center, Rotterdam, Netherlands, 5Amgen, Uxbridge, United Kingdom, 6Amgen BV, Breda, Netherlands
OBJECTIVES: Chemotherapy-induced FN can result in reduced chemotherapy delivery, unplanned hospitalizations, increased mortality risk, and substantial HCU. Little is known about FN-related HCU among cancer patients in Dutch clinical practice. METHODS: Data from incident adult BC and NHL-patients from 1998–2007 were obtained from the PHARMO Record Linkage System, including pharmacy, hospital, and lab data. Eligible patients had ≥12 months medical history and received chemotherapy within 6 months after cancer diagnosis. Patients developing FN within 6 months after first chemotherapy (“FN-patients”) were matched 1:2 on gender, birth-year, and chemotherapy-regimen to patients without FN (“non-FN-patients”). HCU-data (hospitalizations, medical procedures, drug use [number dispensed]) was tallied from entry date (date of FN or matched date for non-FN-patients) for up to 3 months. Statistics are descriptive with crude odds ratios (OR). RESULTS: As a result, 80/1033 (8%) BC-patients developed FN. 95/486 (20%) NHL-patients developed FN. Eighty and 89 FN-patients were matched, respectively. More FN-patients than non-FN-patients were hospitalized in the first month after entry date (BC: 73% vs 14% [OR=23.0; 95%CI:(8.3-63.7)]; NHL: 78% vs 33% [OR=7.6; 95%CI:(3.9-15.1)]). These differences were mainly due to FN-related hospitalizations (BC: 55% vs 1%; NHL: 47% vs 4%). FN-patients also had a longer mean length of stay per all-cause hospitalization (BC: 4.6 vs 1.9 days; NHL: 10.1 vs 3.0 days). Mean number of total drugs dispensed in the first month was higher in FN-patients than in non-FN-patients (BC: 5.8 vs 3.1; NHL: 8.5 vs 3.6), as was use of anti-infectious agents (BC: 99% vs 11%; NHL: 96% vs 20%) and other non-chemotherapy drugs. More FN-patients than non-FN-patients had medical procedures (BC: 14% vs 3%; NHL: 13% vs 8%). HCU-differences between FN-patients and non-FN-patients were maintained after 3 months. CONCLUSIONS: HCU in BC and NHL-patients with FN in the Netherlands is substantial. Reduction of FN may improve quality of life and save resources.
Conference/Value in Health Info
2012-11, ISPOR Europe 2012, Berlin, Germany
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PCN141
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology